---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037162"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T13:34:55.124631+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q2 net loss $72.1M ($1.66/sh); revenue $20M; RGX-121 enrollment complete

## Summary
- Net loss widened to $72.1M vs $68.2M YoY; diluted EPS -$1.66.
- Revenue fell to $20.0M from $32.6M; Zolgensma royalty revenue down to $19.0M.
- Cash, equivalents and marketable securities $415.4M; runway into 2025.
- Completed enrollment (10 patients) in Phase III CAMPSIITE trial for RGX-121; BLA filing planned 2024.
- ABBV-RGX-314 suprachoroidal dose level 3 with short-course steroids showed zero intraocular inflammation (N=39).

## SEC filing metadata
- accession: 0000950170-23-037162
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017023037162/0000950170-23-037162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017023037162/rgnx-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037162
- JSON: https://secwatch.observer/filing/0000950170-23-037162.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.